Literature DB >> 22639547

Pooled analyses of the associations of polymorphisms in the GRK4 and EMILIN1 genes with hypertension risk.

Chibo Liu1, Bo Xi.   

Abstract

BACKGROUND: The GRK4 and EMILIN1 genes have been suggested to be involved in the development of hypertension. However, the results have been inconsistent. In this study, a meta-analysis was performed to clarify the associations of polymorphisms in the GRK4 and EMILIN1 genes with hypertension risk.
METHODS: Published literature from PubMed and Embase databases were retrieved. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed- or random-effects model.
RESULTS: Five studies for polymorphisms in the GRK4 gene and five studies for polymorphisms in the EMILIN1 gene were identified. The results suggested that rs1801058 polymorphism in the GRK4 gene was inversely associated with hypertension among East Asians (TT vs. CC: OR=0.39, 95%CI 0.28-0.55) and positively associated with hypertension among Europeans (TT vs. CC: OR= 2.38, 95%CI 1.38-4.10). Rs2960306 polymorphism in the GRK4 gene was significantly associated with hypertension among Europeans (TT vs. GG: OR=1.92, 95%CI 1.13-3.27). The significant associations were also observed for rs2011616 and rs2304682 polymorphisms in the EMILIN1 gene among Japanese (rs2011616: AA vs. GG: OR=0.38, 95%CI 0.18-0.82; rs2304682: GG vs. CC: OR=0.37, 95%CI 0.17-0.81) but not among Chinese.
CONCLUSIONS: This meta-analysis suggested that rs1801058 polymorphism in the GRK4 gene was associated with hypertension in East Asians and Europeans. The significant association was also found for rs2960306 polymorphism in the GRK4 gene among Europeans. In addition, there were significant associations of rs2011616 and rs2304682 polymorphisms in the EMILIN1 gene with hypertension among Japanese.

Entities:  

Keywords:  EMILIN1; GRK4; Hypertension; Meta-analysis.; Polymorphism

Mesh:

Substances:

Year:  2012        PMID: 22639547      PMCID: PMC3360431          DOI: 10.7150/ijms.4171

Source DB:  PubMed          Journal:  Int J Med Sci        ISSN: 1449-1907            Impact factor:   3.738


Introduction

Hypertension is associated with stroke and cardiovascular disease which are major causes of global health burden 1. Epidemiological studies have suggested that environmental factors (e.g. excess alcohol consumption, increased salt intake, and less physical activity) could increase the risk of hypertension 2. However, many studies supported that hypertension is a complex disease resulting from the interactions of genes and environmental factors 3. Twin studies have shown that approximately 50% of blood pressure variation was determined by genetics 4. Therefore, the identification of new susceptibility genes would help further elucidate the underlying molecular mechanisms of hypertension. G protein-coupled receptor kinase 4 (GRK4) has been involved in the development of hypertension since it plays an important role in the desensitization of the dopamine receptor 1(D1) 5. Dopamine contributes to sodium balance by facilitating natriuresis through activation of D1 on the renal proximal tubules 6. Therefore, polymorphisms in the GRK4 gene might contribute to sodium retention and hypertension through inactivation of the D1 receptor. A486V (rs1801058), R65L (rs2960306) and A142V (rs1024323) polymorphisms were the most frequently studied ones. However, the results have been inconsistent. The elastin microfibril interfacer-1(EMILIN1) is implicated in stabilise elastin and related microfibrils, and affects vessel compliance and the blood pressure (BP). Evidences have suggested that EMILIN1 inhibits TGF-β signaling by specifically binding to the proTGF-β precursor and plays a key role in BP homeostasis 7. To date, three polymorphisms (rs2011616, rs2304682 and rs3754734) in the EMILIN1 gene have been reported to be associated with BP or hypertension in different ethnic populations. However, the results also have been conflicting. Therefore, in this study, we performed the meta-analysis to clarify the associations of polymorphisms in the GRK4 and EMILIN1 genes with hypertension risk across different ethnic populations.

Materials and methods

Literature and search strategy

We searched the literature databases including PubMed and Embase. The search strategy to identify all possible studies involved the use of the following key words: (G-protein coupled receptor Kinase-4 or GRK4 or the elastin microfibril interfacer-1 or EMILIN1) and (variant or variation or polymorphism) and hypertension. All related studies published in English and Chinese languages were included. The reference lists of retrieved articles were hand-searched. If more than one article were published using the same data, only the study with largest sample size was included. The literature search was updated on September 13, 2011.

Inclusion criteria and data extraction

The studies included in the meta-analysis must meet all the following inclusion criteria: (1) evaluated the association of polymorphism in the GRK4 or EMILIN1 gene with hypertension; (2) used case-control or cohort design; (3) provided sufficient data for calculation of odds ratio (OR) with 95% confidence interval (CI). The following information was extracted from each study: (1) name of the first author; (2) year of publication; (3) country; (4) gender frequency and mean age of subjects in hypertensive cases and controls; (5) sample size of cases and controls; (6) genotype distribution in cases and controls; and (7) P value for Hardy-Weinberg equilibrium (HWE) test in controls. The two authors independently assessed the articles for compliance with the inclusion/exclusion criteria, resolved disagreements and reached a consistent decision.

Statistical analysis

The associations of polymorphisms in the GRK4 or EMILIN1 gene with hypertension were estimated by calculating pooled ORs and 95% CIs under a co-dominant, a dominant and a recessive genetic model, respectively. The significance of pooled OR was determined by Z test (p<0.05 was considered statistically significant). Q test was performed to evaluate to the between-study heterogeneity. A random- (DerSimonian-Laird method 8) or fixed- (Mantel-Haenszel method 9) effects model was used to calculate pooled OR in the presence (p<=0.10) or absence (p>0.10) of heterogeneity, respectively. Subgroup analysis by ethnicity was performed. Begg's funnel plot, a scatter plot of effect against a measure of study size, was generated as a visual aid to detect bias or systematic heterogeneity 10. Publication bias was assessed by Egger's test 11 (p<0.05 was considered statistically significant). Data analysis was performed using STATA version 11 (StataCorp LP, College Station, Texas, USA). To correct for multiple comparisons, the false discovery rate (FDR) approach was used 12. FDR analysis (0.05 as criteria) was applied for four genetic models, six polymorphisms, 12 groups for three polymorphisms in the GRK4 gene and 7 groups for three polymorphisms in EMILIN1 gene simultaneously (number of tests: 4×4×3+4×7=76).

Results

Characteristics of the studies

The literature search identified a total of 41 potentially relevant papers. Of these, 27 papers were excluded because of obvious irrelevance by reading the titles and abstracts. In addition, three reviews 13-15, one duplicated publication 16, and one paper 17 which assessed the associations of polymorphisms with salt-sensitive hypertension was excluded. It should be noted that the paper by Shen et al. 23 contained two studies. Finally, five studies for polymorphisms in the GRK4 gene 18-22 and five studies for polymorphisms in the EMILIN1 gene 23-26 met the inclusion criteria and were included in the meta-analysis. The characteristics of the included studies were listed in Table 1.
Table 1

Characteristics of the studies included in the meta-analysis.

StudyCountryEthnicityGender (M/F)Age, mean±SD, yearsSample SizePolymorphismsDefinitions (SBP/DBP, mmHg)
CasesControlsCasesControlsCasesControlsHypertensionControls
GRK4 gene
Bengra, 2002ItalyEuropeanNANANANA6060rs2960306; rsl024323; rs1801058≥140/90<140/90
Williams, 2004GhanaAfricanNANANANA12651rs2960306; rsl024323; rs1801058≥160/95 a<140/90
Speirs, 2004Australiaand UKEuropean67/101178/13454±1247±11168312rs2960306; rsl024323; rs1801058≥140/90<130/90
Wang, 2006ChinaEast Asian262/241257/23353.6±9.353.5±9.2503490rs2960306; rsl024323; rs1801058≥160/100<140/90
Martinez Cantarin,2010USAfrican100/73109/13040±636±8173239rs2960306; rsl024323; rs1801058≥140/90 b<130/80
EMILIN1 gene
Shen,2009ChinaEast Asian262/241257/23353.6 ± 9.353.5 ± 9.2503490rs2011616; rs2304682; rs3754734≥160/100 b<140/90
Shen,2009ChinaEast Asian393/421401/37854.5 ± 10.753.5 ± 9.7814779rs2011616; rs3754734≥160/100 b<140/90
Shimodaira,2010JapanEast Asian193/94157/9649.8 ± 6.851.1 ± 9.9287253rs2011616; rs2304682≥160/100<130/85
Oh,2011SingaporeEast Asian268/199157/31849.4±11.947.3±8.7467475rs2011616≥140/90 c<134/84
Mi,2011ChinaEast AsianNANA52.5±9.449.0±10.3201202rs2011616; rs2304682; rs3754734≥140/90<140/90

NA, not available.

a or who had been previously diagnosed as hypertensive.

b or currently taking antihypertensive medications.

c or mean 24-h ambulatory blood pressure ≥135/85mmHg.

Meta-analysis results

Regarding GRK4 gene, five studies (1000 cases and 1059 controls) for rs1801058 polymorphism, five studies (1012 cases and 1119 controls) for rs2960306 polymorphism, and five studies (1018 cases and 1004 controls) for rs1024323 polymorphism were included in the meta-analysis. The results indicated no significant association for all three polymorphisms with the risk of hypertension under all genetic models (Table 2). Further subgroup analysis by ethnicity showed that rs1801058 polymorphism was inversely associated with hypertension among East Asians (Chinese) (TT vs. CC: OR=0.39, 95%CI 0.28-0.55; CT vs. CC: OR=0.55, 95%CI 0.40-0.75; TT+CT vs. CC: OR=0.48, 95%CI 0.36-0.64; TT vs. CT+CC: OR=0.57, 95%CI 0.43-0.76), but positively associated with hypertension among Europeans (TT vs. CC: OR= 2.38, 95%CI 1.38-4.10; CT vs. CC: OR=1.66, 95%CI 1.08-2.55; TT+CT vs. CC: OR=1.82, 95%CI 1.21-2.74; TT vs. CT+CC: OR=1.70, 95%CI 1.07-2.70). Rs2960306 polymorphism was significantly associated with hypertension among Europeans (TT vs. GG: OR=1.92, 95%CI 1.13-3.27; TT vs. GT+GG: OR=1.94, 95%CI 1.19-3.18) (Table 2).
Table 2

Pooled ORs and 95%CIs of the associations between polymorphisms in the GRK4 gene and hypertension risk.

ContrastsNo. of studies(cases/ controls)Homogeneous co-dominant modelHeterogeneous co-dominant modelDominant modelRecessive model
OR95% CIP HOR95% CIP HOR95% CIP HOR95% CIP H
rs1801058
All5 (1000/1059)1.260.42-3.800.0000.950.57-1.580.0011.010.54-1.860.0001.150.56-2.350.002
European2 (205/308)2.381.38-4.100.6241.661.08-2.550.7591.821.21-2.740.6361.701.07-2.700.629
African2 (292/261)1.060.32-3.480.2820.690.46-1.040.3540.720.49-1.070.1951.060.35-3.830.317
East Asian (Chinese)1 (503/490)0.390.28-0.55-0.550.40-0.75-0.480.36-0.64-0.570.43-0.76-
rs2960306
All5 (1012/1119)1.220.86-1.730.2390.910.74-1.110.9550.940.77-1.150.6881.230.90-1.680.178
European2 (220/372)1.921.13-3.270.7950.980.68-1.410.7921.130.80-1.600.6501.941.19-3.180.863
African2 (289/257)0.950.56-1.600.6660.970.64-1.450.9440.960.65-1.410.9070.960.61-1.500.572
East Asian (Chinese)1 (503/490)0.620.22-1.76-0.830.61-1.13-0.810.60-1.10-0.650.23-1.83-
rs1024323
All5 (1018/1004)0.980.70-1.360.1850.920.75-1.130.4870.910.75-1.110.2920.990.75-1.290.376
European2 (228/249)1.500.84-2.660.8561.090.74-1.610.6061.170.81-1.690.7711.430.84-2.430.692
African2 (287/265)0.980.57-1.680.2271.000.60-1.660.1910.990.60-1.610.1790.980.68-1.400.751
East Asian (Chinese)1 (503/490)0.570.30-1.10-0.820.63-1.08-0.790.61-1.03-0.610.32-1.16-

P H, P value for heterogeneity based on Q test.

Regarding EMILIN1 gene, five studies (2262 cases and 2189 controls) for rs2011616 polymorphism, three studies (991 cases and 945 controls) for rs2304682 polymorphism, and three studies (1485 cases and 1468 controls) for rs3754734 polymorphism were included in the meta-analysis. Overall, there was no significant association between three polymorphisms and hypertension among East Asians (Table 3). In the stratified analysis, the significant association was observed for rs2011616 and rs2304682 among Japanese (rs2011616 AA vs. GG: OR=0.38, 95%CI 0.18-0.82; GA vs. GG: OR=0.67, 95%CI 0.46-0.97; AA+GA vs. GG: OR=0.61, 95%CI 0.43-0.87; AA vs. GA+GG: OR=0.44, 95%CI 0.21-0.93. rs2304682 GG vs. CC: OR=0.37, 95%CI 0.17-0.81; CG vs. CC: OR=0.67, 95CI 0.46-0.97; CG+GG vs. CC: OR=0.61, 95%CI 0.43-0.87; GG vs. CG+CC: OR=0.42, 95%CI 0.19-0.92) but not among Chinese (Table 3).
Table 3

Pooled ORs and 95%CIs of the associations between polymorphisms in the EMILIN1 gene and hypertension risk.

ContrastsNo. of studies(cases/controls)Homogeneous co-dominant modelHeterogeneous co-dominant modelDominant modelRecessive model
OR95% CIP HOR95% CIP HOR95% CIP H
rs2011616
All5 (2262/2189)0.890.70-1.120.1050.890.70-1.120.0150.880.69-1.120.0060.920.74-1.160.258
Chinese4 (1975/1936)0.970.76-1.240.4780.940.73-1.210.0200.950.75-1.210.0201.000.79-1.270.777
Japanese1 (287/253)0.380.18-0.82-0.670.46-0.97-0.610.43-0.87-0.440.21-0.93-
rs2304682
All3 (991/945)1.050.39-2.810.0011.060.68-1.670.0061.060.62-1.810.0001.000.45-2.220.010
Chinese2 (704/692)1.660.64-4.340.0321.240.99-1.550.1241.370.86-2.170.0471.420.66-3.050.075
Japanese1 (287/253)0.370.17-0.81-0.670.46-0.97-0.610.43-0.87-0.420.19-0.92-
rs3754734
All (Chinese)3 (1485/1468)1.090.86-1.390.4851.210.83-1.770.0061.190.84-1.680.0090.990.79-1.250.970

P H, P value for heterogeneity based on Q test.

The significant associations for the polymorphisms above remained even after FDR was applied, although they disappeared in some genetic models of the polymorphisms.

Discussion

To our knowledge, this is the first meta-analysis which comprehensively assessed the associations of polymorphisms in the GRK4 and EMILIN1genes with hypertension risk. To date, several studies have investigated the associations among different ethnic populations. However, the findings have been conflicting, with results of increased, decreased, or no risk of hypertension for the same polymorphism. The discrepant results might be due to many reasons such as the differences in statistical power, recruitment procedures of the study population, and the genetic and environmental backgrounds. The present meta-analysis indicated that rs1801058 polymorphism in the GRK4 gene was inversely associated with hypertension among East Asians, but positively associated with hypertension among Europeans. In addition, there was a significant association between rs2960306 in the GRK4 gene and hypertension among Europeans. We also observed significant associations of rs2011616 and rs2304682 polymorphisms in the EMILIN1 gene with hypertension among Japanese. It is possible that the effect sizes of genetic factors predisposing to human diseases are different across various ethnic populations 27. Indeed, the distributions of most polymorphisms are much different in the various ethnic populations. Taking rs1801058 polymorphism in the GRK4 gene for an example, the frequency of T allele is about 0.398 in European population; while it is about 0.494 in Chinese, 0.529 in Japanese, and 0.097 in African (HapMap data). Moreover, the exposure to environmental factors might be also different across different ethnic populations. Therefore, the subgroup analysis based on ethnicity was performed. The results suggested this polymorphism was inversely associated with hypertension in East Asians, but positively associated with hypertension in Europeans. However, no statistically significant association was observed in Africans. The effect of ethnic differences was also demonstrated for rs2960306 polymorphism, with the significant association only in Europeans. However, the effect of rs2011616 and rs2304682 polymorphisms in the EMILIN1gene on hypertension among Japanese could not be explained by ethnic differences since the genetic backgrounds are very similar between Chinese and Japanese populations. Therefore, it is possible that the effect differences were due to different environmental backgrounds or gene-environment interactions. The mechanisms of how the rs1801058 and rs2960306 polymorphisms in the GRK4 gene and rs2011616 and rs2304682 polymorphisms in the EMILIN1 gene influence hypertension susceptibility among East Asians or Europeans are still unclear. GRK4 is expressed in the nephron segments of the kidney, where sodium transport is regulated by dopamine and angiotensin II 28. The 4p16.3, where the GRK4 gene located, has been indicated to be important in the development of hypertension 29. Other genes, such as the α-adducin and D5 receptor genes, which close to 4p arm, have also been linked to hypertension. Those three polymorphisms in the GRK4 gene are associated with a constitutive increase in kinase activity in proximal tubule cells from humans with essential hypertension 30. Increases in BP, peripheral vascular resistance and reduces in vessel size have been observed among EMILIN1 knockout animals 7. It has been shown that EMILIN1 links TGF-β maturation to BP homeostasis. In addition, EMILIN1 could bind specially to the proTGF-β precursor and prevent its maturation by furin convertases in the extracellular space, thereby inhibiting TGF-β signaling 7. The current meta-analysis has some advantages compared to other individual studies; however, it does have some limitations. First, the meta-analysis was based primarily on unadjusted ORs and CIs because of the unavailability of adjusted estimates from the primary publications, and then the confounding factors might influence the precision of effect estimates. Second, the effects of gene-gene/ gene-environment interactions were not addressed in this meta-analysis. Third, the statistical power was limited in the subgroup analysis based on ethnicity. Therefore, the conclusions should be interpreted with caution. Fourth, more than one polymorphism in GRK4 or EMILIN1gene was investigated among each study; however, the haplotype analysis was not performed among most studies, which impeded us for the further meta-analysis. In summary, this meta-analysis suggested that rs1801058 polymorphism in the GRK4 gene was associated with hypertension in East Asians and Europeans; rs2960306 polymorphism in the GRK4 gene was significantly associated with hypertension among Europeans. In addition, there was a significant association of rs2011616 and rs2304682 polymorphisms in the EMILIN1gene with hypertension among Japanese. However, further studies are needed to investigate the role of polymorphisms in the GRK4 and EMILIN1 genes in the pathogenesis of hypertension.

Potential publication bias

No publication bias was detected for all six polymorphisms by Egger's test (all P>0.05).
  28 in total

1.  Association study with 33 single-nucleotide polymorphisms in 11 candidate genes for hypertension in Chinese.

Authors:  Dongfeng Gu; Shaoyong Su; Dongliang Ge; Shufeng Chen; Jianfeng Huang; Biao Li; Runsheng Chen; Boqin Qiang
Journal:  Hypertension       Date:  2006-04-24       Impact factor: 10.190

2.  Single-nucleotide polymorphisms for diagnosis of salt-sensitive hypertension.

Authors:  Hironobu Sanada; Junichi Yatabe; Sanae Midorikawa; Shigeatsu Hashimoto; Tsuyoshi Watanabe; Jason H Moore; Marylyn D Ritchie; Scott M Williams; John C Pezzullo; Midori Sasaki; Gilbert M Eisner; Pedro A Jose; Robin A Felder
Journal:  Clin Chem       Date:  2006-01-26       Impact factor: 8.327

3.  Association study of G protein-coupled receptor kinase 4 gene variants with essential hypertension in northern Han Chinese.

Authors:  Yaping Wang; Biao Li; Weiyan Zhao; Pei Liu; Qi Zhao; Shufeng Chen; Hongfan Li; Dongfeng Gu
Journal:  Ann Hum Genet       Date:  2006-11       Impact factor: 1.670

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

5.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

6.  [Association of EMILIN1 gene polymorphism with essential hypertension in Mongolian].

Authors:  Dong-qing MI; Bu-yun WANG; Hao Sun; Xiao-qin HUANG; Xiao-chen CHEN; Di ZONG; Liang YU; Lei SHI; Zhao-qing YANG; Li Shi; Jiayou Chu
Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi       Date:  2011-04

7.  G protein-coupled receptor kinase 4 gene variants in human essential hypertension.

Authors:  Robin A Felder; Hironobu Sanada; Jing Xu; Pei-Ying Yu; Zheng Wang; Hidetsuna Watanabe; Laureano D Asico; Wei Wang; Shaopeng Zheng; Ikuyo Yamaguchi; Scott M Williams; James Gainer; Nancy J Brown; Debra Hazen-Martin; Lee-Jun C Wong; Jean E Robillard; Robert M Carey; Gilbert M Eisner; Pedro A Jose
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 8.  Advances in genetic hypertension.

Authors:  Scott S Williams
Journal:  Curr Opin Pediatr       Date:  2007-04       Impact factor: 2.856

9.  Multilocus analysis of hypertension: a hierarchical approach.

Authors:  Scott M Williams; Marylyn D Ritchie; John A Phillips; Elliot Dawson; Melissa Prince; Elvira Dzhura; Alecia Willis; Amma Semenya; Marshall Summar; Bill C White; Jonathan H Addy; John Kpodonu; Lee-Jun Wong; Robin A Felder; Pedro A Jose; Jason H Moore
Journal:  Hum Hered       Date:  2004       Impact factor: 0.444

10.  Genotyping of essential hypertension single-nucleotide polymorphisms by a homogeneous PCR method with universal energy transfer primers.

Authors:  Chikh Bengra; Theodore E Mifflin; Yuri Khripin; Paolo Manunta; Scott M Williams; Pedro A Jose; Robin A Felder
Journal:  Clin Chem       Date:  2002-12       Impact factor: 8.327

View more
  12 in total

1.  Structure and Function of the Hypertension Variant A486V of G Protein-coupled Receptor Kinase 4.

Authors:  Samantha J Allen; Gopal Parthasarathy; Paul L Darke; Ronald E Diehl; Rachael E Ford; Dawn L Hall; Scott A Johnson; John C Reid; Keith W Rickert; Jennifer M Shipman; Stephen M Soisson; Paul Zuck; Sanjeev K Munshi; Kevin J Lumb
Journal:  J Biol Chem       Date:  2015-07-01       Impact factor: 5.157

Review 2.  The evolving impact of g protein-coupled receptor kinases in cardiac health and disease.

Authors:  Priscila Y Sato; J Kurt Chuprun; Mathew Schwartz; Walter J Koch
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

Review 3.  Genomics and Pharmacogenomics of Salt-sensitive Hypertension.

Authors:  Ines Armando; Van Anthony M Villar; Pedro A Jose
Journal:  Curr Hypertens Rev       Date:  2015

4.  Genomics and pharmacogenomics of salt-sensitive hypertension Minireview.

Authors:  Ines Armando; Van Anthony M Villar; Pedro A Jose
Journal:  Curr Hypertens Rev       Date:  2015

Review 5.  G-protein-coupled receptor kinase 2 and hypertension: molecular insights and pathophysiological mechanisms.

Authors:  Gaetano Santulli; Bruno Trimarco; Guido Iaccarino
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-03-27

Review 6.  Gastrorenal Axis.

Authors:  Pedro A Jose; Robin A Felder; Zhiwei Yang; Chunyu Zeng; Gilbert M Eisner
Journal:  Hypertension       Date:  2016-04-04       Impact factor: 10.190

7.  Comprehensive assessment of the association of WNK4 polymorphisms with hypertension: evidence from a meta-analysis.

Authors:  Xiao-gang Guo; Jie Ding; Hui Xu; Tian-ming Xuan; Wei-quan Jin; Xiang Yin; Yun-peng Shang; Fu-rong Zhang; Jian-hua Zhu; Liang-rong Zheng
Journal:  Sci Rep       Date:  2014-09-30       Impact factor: 4.379

Review 8.  A narrative review on the interaction between genes and the treatment of hypertension and breast cancer.

Authors:  Wenjuan Wang; Qingjian He; Haodong Zhang; Chenchen Zhuang; Qiongying Wang; Caie Li; Runmin Sun; Xin Fan; Jing Yu
Journal:  Ann Transl Med       Date:  2021-05

9.  TGF-β mediates early angiogenesis and latent fibrosis in an Emilin1-deficient mouse model of aortic valve disease.

Authors:  Charu Munjal; Amy M Opoka; Hanna Osinska; Jeanne F James; Giorgio M Bressan; Robert B Hinton
Journal:  Dis Model Mech       Date:  2014-08       Impact factor: 5.758

Review 10.  Association between GRK4 and DRD1 gene polymorphisms and hypertension: a meta-analysis.

Authors:  He Zhang; Zhao-qing Sun; Shuang-shuang Liu; Li-na Yang
Journal:  Clin Interv Aging       Date:  2015-12-23       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.